CoChat

A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors

Open access

The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.

Abstract

Background: Brontictuzumab is a monoclonal antibody that targets Notch1 and inhibits pathway activation. The purpose of this first-in-human study was to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, immunogenicity and preliminary efficacy of brontictuzumab in patients with solid tumors. Patients and methods: Subjects with selected refractory solid tumors were eligible. Brontictuzumab was administered intravenously at various dose levels and schedule during dose escalation, and at 1.5 mg/kg every 3 weeks (Q3W) during expansion. Evidence of Notch1 pathway activation as determined by an immunohistochemistry assay was required for entry in the expansion cohort. Adverse events were graded according to the NCI-CTCAE v 4.03. Efficacy was assessed by RECIST 1.1. Results: Forty-eight subjects enrolled (33 in dose escalation and 15 in the expansion phase). The MTD was 1.5 mg/kg Q3W. Dose-limiting toxicities were grade 3 diarrhea in two subjects and grade 3 fatigue in one subject. The most common drug-related adverse events of any grade were diarrhea (71%), fatigue (44%), nausea (40%), vomiting (21%), and AST increase (21%). Brontictuzumab exhibited nonlinear pharmacokinetics with dose-dependent terminal half-life ranging 1-4 days. Clinical benefit was seen in 6 of 36 (17%) assessable subjects: 2 had unconfirmed partial response (PR) and 4 subjects had prolonged (≥ 6 months) disease stabilization (SD). Both PRs and three prolonged SD occurred in adenoid cystic carcinoma (ACC) subjects with evidence of Notch1 pathway activation. Pharmacodynamic effects of brontictuzumab were seen in patients' blood and tumor. Conclusion: Brontictuzumab was well tolerated at the MTD. The main toxicity was diarrhea, an on-target effect of Notch1 inhibition. An efficacy signal was noted in subjects with ACC and Notch1 pathway activation. ClinicalTrials.gov identifier: NCT01778439.

Overview

Integrity signals

Registry

Crossref · 10.1093/annonc/mdy171

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Cited by

See all 138

Metadata

Authors
Ferrarotto, R., Eckhardt, G., Patnaik, A., LoRusso, P., Faoro, L., Heymach, J. V., Kapoun, A. M., Xu, L., & Munster, P.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • University of Colorado Denver (US)
  • South Texas Accelerated Research Therapeutics (US)
  • Yale University (US)
  • OncoMed (United States) (US)
  • University of California, San Francisco (US)
Corresponding author
Ferrarotto, R.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2018-07
Volume
29
Issue
7
Pages
1561-1568
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2800138464
Cited by
138
References
28
Citations by year
2026: 12 · 2025: 16 · 2024: 26 · 2023: 26 · 2022: 20 · 2021: 16 · 2020: 10 · 2019: 11 · 2018: 1
FWCI
3.56
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
OncoMed Pharmaceuticals Inc.
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
Keywords
monoclonal antibodies, solid tumors, maximum tolerated dose, pharmacokinetics, immunogenicity, diarrhea, adenoid cystic carcinoma, pharmacodynamics, refractory cancer, dose-limiting toxicity
MeSH terms
Antineoplastic Agents, Immunological, Adult, Aged, Antibodies, Monoclonal, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasms, Prognosis, Tissue Distribution, Cohort Studies, Survival Rate, Salvage Therapy, Drug Resistance, Neoplasm, Maximum Tolerated Dose, Receptor, Notch1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. https://app.cochat.ai/papers/10.1093/annonc/mdy171
The paper
Ferrarotto, R., Eckhardt, G., Patnaik, A., LoRusso, P., Faoro, L., Heymach, J. V., Kapoun, A. M., Xu, L., & Munster, P. (2018). A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Annals of Oncology. https://doi.org/10.1093/annonc/mdy171

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.